Opium (Opioid) Addiction - Pipeline Review, H1 2018

Opium (Opioid) Addiction - Pipeline Review, H1 2018

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Opium (Opioid) Addiction - Pipeline Review, H1 2018, provides an overview of the Opium (Opioid) Addiction (Central Nervous System) pipeline landscape.

Opioid Addiction develops after using opioids regularly for a period of time. Prolonged use of opiates can lead to nerve damage within the brain that causes cells to stop producing endogenous opiates (natural painkillers known as endorphins). This can lead to an inability for the body to stop pain because there are no endorphins to mask the pain initially. The degeneration of the nerve cells that reduce pain can lead to a physical dependence on opiates as an external supply source. Signs and symptoms include increased general anxiety, euphoria, psychosis, depression, high blood pressure, decreased appetite, physical agitation, difficulty sleeping and pain in the bones. The predisposing factors include age, a personal history of substance abuse, and family history of substance abuse, cigarette dependency and psychologic stress.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Opium (Opioid) Addiction - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Opium (Opioid) Addiction (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Opium (Opioid) Addiction (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Opium (Opioid) Addiction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 4, 6, 1, 14, 3 and 2 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 3 molecules, respectively.

Opium (Opioid) Addiction (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Opium (Opioid) Addiction (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Opium (Opioid) Addiction (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Opium (Opioid) Addiction (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Opium (Opioid) Addiction (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Opium (Opioid) Addiction (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Opium (Opioid) Addiction (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Opium (Opioid) Addiction (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Opium (Opioid) Addiction - Overview
Opium (Opioid) Addiction - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Opium (Opioid) Addiction - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Opium (Opioid) Addiction - Companies Involved in Therapeutics Development
Addex Therapeutics Ltd
Aoxing Pharmaceutical Company Inc
BioCorRx Inc
BioDelivery Sciences International Inc
Camurus AB
Fabentech SA
Indivior Plc
Insys Therapeutics Inc
iX Biopharma Ltd
Nemus Bioscience Inc
Novartis AG
Omeros Corp
Opiant Pharmaceuticals Inc
Orexigen Therapeutics Inc
Orexo AB
Pfizer Inc
Relmada Therapeutics Inc
Syntropharma Ltd
Titan Pharmaceuticals Inc
Zynerba Pharmaceuticals Inc
Opium (Opioid) Addiction - Drug Profiles
(buprenorphine + naloxone ) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(buprenorphine + naloxone) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(buprenorphine hydrochloride + naloxone hydrochloride) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
18-MC - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ADX-71441 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ADX-88178 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ANS-6637 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antibody for Poisoning, Drug Overdose and Opioid Addiction - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AQU-010 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BPRX-060312 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
buprenorphine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
buprenorphine hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
buprenorphine hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
buprenorphine hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
buprenorphine hydrochloride depot - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
buprenorphine MR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cannabidiol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Canquit-O - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FP-004 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
mavoglurant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MP-1104 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
naltrexone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
naltrexone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
naltrexone hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
naltrexone hydrochloride SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NB-2111 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NT-814 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OMS-405 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OMS-527 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OPNT-005 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OREX-1019 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PF-4363467 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PF-5006739 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PMZ-2123 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize D3 Receptor for Opioid Addiction - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Target Calcium Activated Potassium Channel, KOR1, and MOR1 for Chronic pain and Opioid Dependence - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine for Opium Addiction - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Opium (Opioid) Addiction - Dormant Projects
Opium (Opioid) Addiction - Discontinued Products
Opium (Opioid) Addiction - Product Development Milestones
Featured News & Press Releases
Feb 13, 2018: Heroin vaccine blocks lethal overdose
Feb 12, 2018: BioCorRx Announces Results of Pre-IND meeting with FDA for Sustained Release Naltrexone Implant, BICX102
Feb 08, 2018: Indivior Files Complaints Asserting New SUBOXONE Film Patent Against ANDA-filers
Jan 22, 2018: Titan In Discussions With Braeburn Regarding U.S. Probuphine Commercialization
Jan 21, 2018: Braeburn Receives Complete Response Letter for CAM2038 Injectable Buprenorphine Depot
Jan 05, 2018: BioCorRx Retains Regulatory Drug Expert Priya Jambhekar and CMC Expert Bruce Firestone
Jan 02, 2018: BioCorRx CEO, Brady Granier, Appears on Fox & Friends to Discuss the Opioid Epidemic
Dec 19, 2017: BioCorRx Submits Pre-IND Package to FDA for its Naltrexone Implant, BICX102
Dec 18, 2017: Opiant Pharma Announces Publication of New Pre-Clinical Data Supporting Potential of OPNT005 as a Heroin Vaccine
Dec 18, 2017: New Vaccine Technology Shows Promise as a Tool to Combat the Opioid Crisis
Nov 27, 2017: European Medicines Agency Accepts Titan Pharmaceuticals Marketing Authorization Application For Probuphine
Nov 20, 2017: Liberate Pain Management Introduces Suboxone Therapy and Other New Services
Nov 14, 2017: Opioid treatment drugs have similar outcomes once patients initiate treatment
Nov 07, 2017: Camurus to present at Jefferies 2017 London Healthcare Conference
Nov 01, 2017: Braeburn Announces FDA Advisory Committee Recommends Approval of CAM2038 Buprenorphine Depot for the Treatment of Opioid Use Disorder
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

List of Tables
Number of Products under Development for Opium (Opioid) Addiction, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Products under Development by Universities/Institutes, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..1), H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Opium (Opioid) Addiction - Pipeline by Addex Therapeutics Ltd, H1 2018
Opium (Opioid) Addiction - Pipeline by Aoxing Pharmaceutical Company Inc, H1 2018
Opium (Opioid) Addiction - Pipeline by BioCorRx Inc, H1 2018
Opium (Opioid) Addiction - Pipeline by BioDelivery Sciences International Inc, H1 2018
Opium (Opioid) Addiction - Pipeline by Camurus AB, H1 2018
Opium (Opioid) Addiction - Pipeline by Fabentech SA, H1 2018
Opium (Opioid) Addiction - Pipeline by Indivior Plc, H1 2018
Opium (Opioid) Addiction - Pipeline by Insys Therapeutics Inc, H1 2018
Opium (Opioid) Addiction - Pipeline by iX Biopharma Ltd, H1 2018
Opium (Opioid) Addiction - Pipeline by Nemus Bioscience Inc, H1 2018
Opium (Opioid) Addiction - Pipeline by Novartis AG, H1 2018
Opium (Opioid) Addiction - Pipeline by Omeros Corp, H1 2018
Opium (Opioid) Addiction - Pipeline by Opiant Pharmaceuticals Inc, H1 2018
Opium (Opioid) Addiction - Pipeline by Orexigen Therapeutics Inc, H1 2018
Opium (Opioid) Addiction - Pipeline by Orexo AB, H1 2018
Opium (Opioid) Addiction - Pipeline by Pfizer Inc, H1 2018
Opium (Opioid) Addiction - Pipeline by Relmada Therapeutics Inc, H1 2018
Opium (Opioid) Addiction - Pipeline by Syntropharma Ltd, H1 2018
Opium (Opioid) Addiction - Pipeline by Titan Pharmaceuticals Inc, H1 2018
Opium (Opioid) Addiction - Pipeline by Zynerba Pharmaceuticals Inc, H1 2018
Opium (Opioid) Addiction - Dormant Projects, H1 2018
Opium (Opioid) Addiction - Discontinued Products, H1 2018

List Of Figures

List of Figures
Number of Products under Development for Opium (Opioid) Addiction, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Number of Products by Top 10 Targets, H1 2018
Number of Products by Stage and Top 10 Targets, H1 2018
Number of Products by Top 10 Mechanism of Actions, H1 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
Number of Products by Top 10 Routes of Administration, H1 2018
Number of Products by Stage and Top 10 Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018

Tiotropium Capsule Global Market Review and Outlook

Tiotropium Capsule report is in-depth investigation for Global market. Tiotropium Capsule market was valued at USD XX million Global in 2018 and is forecasted to reach USD XX million by

USD 3000 View Report

Global Opium Market Report 2019 - Market Size, Share, Price, Trend and Forecast

The global market size of Opium is $XX million in 2018 with XX CAGR from 2014 to 2018, and it is expected to reach $XX million by the end of

USD 4000 View Report

Opium (Opioid) Addiction - Pipeline Review, H2 2018

Opium (Opioid) Addiction - Pipeline Review, H2 2018Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Opium (Opioid) Addiction - Pipeline Review, H2 2018, provides an overview of the

USD 2000 View Report

Opium (Opioid) Addiction Global Clinical Trials Review, H1, 2018

Opium (Opioid) Addiction Global Clinical Trials Review, H1, 2018GlobalDatas clinical trial report, Opium (Opioid) Addiction Global Clinical Trials Review, H1, 2018 provides an overview of Opium (Opioid) Addiction clinical trials

USD 2500 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available